Pilot Test of a Community-based Buprenorphine Treatment Intervention
|ClinicalTrials.gov Identifier: NCT01761110|
Recruitment Status : Completed
First Posted : January 4, 2013
Last Update Posted : April 23, 2018
|Condition or disease||Intervention/treatment||Phase|
|Opioid Dependence Injection Drug Use||Behavioral: Community-based buprenorphine treatment (CBBT) intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||77 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Development of a Community-based Buprenorphine Treatment Intervention|
|Study Start Date :||December 2012|
|Actual Primary Completion Date :||February 2014|
|Actual Study Completion Date :||February 2014|
No Intervention: Pre-intervention
Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
Behavioral: Community-based buprenorphine treatment (CBBT) intervention
Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
- initiation of buprenorphine treatment [ Time Frame: 60 days ]Medical record information will be extracted to determine initiation of buprenorphine treatment, which will be defined as a visit with a medical provider in which buprenorphine is prescribed.
- opioid use [ Time Frame: 60 days ]Opioid use will be determined via self-report using the Addiction Severity Index and via urine specimens (e.g., urine toxicology testing).
- HIV risk behaviors [ Time Frame: 60 days ]Drug- and sex-related HIV risk behaviors will be assessed using a standardized risk assessment tool used in NIDA's Clinical Trials Network.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01761110
|United States, New York|
|Washington Heights Corner Project|
|New York, New York, United States, 10033|
|Principal Investigator:||Chinazo Cunningham, MD, MS||Albert Einstein College of Medicine, Inc.|